Back

Short and medium-term safety and tolerability of Sacubitril-Valsartan and Empaglifozin joint intake

25 May 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Chronic Heart Failure – Treatment Pharmacotherapy HFA Premium Access Heart Failure 2019

About the speaker

Photo
Doctor Herminio Morillas Climent

University Hospital Bellvitge, Barcelona (Spain)

55 More presentations in this session

Presentation thumbnail
Small tolerated enalapril doses before ARNI administration predicts adverse events during ARNI up-titration
Doctor A. Ntalianis (Athens, GR)
Abstract
Presentation thumbnail
Prescription of sacubitril/valsartan in a real-world population
Mr J. AGOSTINHO (Lisbon, PT)
Abstract
Presentation thumbnail
Use of sacubitril-valsartan in heart failure with reduced ejection fraction: real world experience
Doctor F. Ferreira (Lisbon, PT)
Abstract
Presentation thumbnail
The dangers of non-heart failure hospitalisation for heart failure patients: frequent medication changes without follow up
Ms E. O'Donoghue (Dublin, IE)
Abstract
Presentation thumbnail
Clinical, echocardiographic and cost improvement after the onset with sacubitril-valsartan in mexican patients with heart failure.
Doctor V. Gomez Leiva (San Salvador, SV)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Chronic Heart Failure – Treatment

The Event

Event poster

Heart Failure 2019

25 May - 28 May 2019
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources